Entry price : 11.48 Fundamentals : - Sector: Medical Products - EPS % Chg (Last Qtr): 90% - EPS % Chg (Previous Qtr): 29% - 3 Year EPS Growth Rate: 0% - EPS Est % Chg (Current Yr): 0% - Sales % Chg (Last Qtr): 73% - Sales % Chg (Previous Qtr): 57% - 3-Year Sales Growth Rate: 32% - Annual Pre -Tax Margin: -81.6%
CTSO broke resistance, if the re-test is strong it'll fly, don't have a price target, good luck happy trading
This is trading around $10 as i speak. I understand that the by making a public offering has mad some investors a little angry but has undoubtedly created opportunity for new investors to join in. they have made a Preliminary Q2 announcement: 58% increase in revenue from Q2 2019. The list of accomplishment for Q2 is very good.
Gotta love these Tech/HC names. Devices are always a fun place when they're moving.
Hello, What is CTSO? Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. News My Thoughts For You I see a bearish divergence on the daily...
CTSO: CytoSorbents Corporation 2020-06-09 07:08:00 CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials
Summary Target $30, Stop $5. (Analyst price-targets around $14-$17). COVID-19 put spotlight on their flagship product Cytosorb, as it gained emergency FDA approval for treatment of severe COVID-19 patients. As further approvals for removal of ticagrelor and rivaroxaban have followed, Cytosorb can potentially become the "standard of care" alongside blood...
After bounced back from 20SMA, $CTSO broke the pivot yesterday and not tries to hold above.
MONMOUTH JUNCTION, N.J., March 25, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, provided an update from its Chief Executive Officer, Dr. Phillip Chan, MD,...
Trade Details Provided on Chart. Swing Trade
NASDAQ:CTSO topped out today and is headed for a retracement. I think it's most likely to go to the 2nd labeled fib level (the middle red line).
CTSO is set to report earnings early next week, given that this was a requested chart, I have not had time to dig in to the company's fundamental financials and create a good estimate of what to expect from its earnings. GIVEN THE TECHNICAL ANALYSIS ALONE: WE are currently hovering a buy zone, and have broken in to it once. At its current level, we are ready to...
$CTSO would like to see this breakout hold for $4.50 to $5 then $5.50